Exosome therapy injects small extracellular vesicles, the packets cells use for paracrine signaling, aiming to deliver stem-cell repair effects without transplanting cells. The human evidence is thin: one small double-blind RCT in severe COVID-19 reported lower mortality, while osteoarthritis and wound claims rest on animal meta-analyses. No exosome product is FDA-approved, and product characterization is the field's core problem.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Has exosome therapy been tested in humans?
Once, properly: a double-blind RCT of placental MSC vesicles in 45 severe COVID-19/ARDS patients reported 19% vs 54% mortality versus placebo. An earlier open-label bone-marrow-MSC exosome study reported safety and improvement signals.34
Do exosomes regenerate joints or skin?
Not proven in humans. A 28-study rat meta-analysis showed improved cartilage histology, but human protocols are unstandardized, and the entry rates skin, hair, and anti-aging uses as commercial extrapolation.2
Are exosome treatments legal in the US?
Therapeutic exosome products require FDA approval and none exists; they must go through the BLA/IND pathway, and the FDA has issued safety alerts after adverse events from unapproved products.
What would change this rating?
Larger controlled trials with characterized products. The entry notes ExoFlo's EXTINGUISH ARDS trial is the first to reach Phase 3 scale, and standardized potency assays are the missing infrastructure.
Core thesis: Exosome / small extracellular vesicle (sEV) therapy is the acellular version of regenerative medicine: instead of implanting living cells, it attempts to deliver the paracrine signals that cells use to coordinate repair, immune resolution, angiogenesis, and phenotype change. The mechanistic case is strong; the clinical case is still early and product-quality-dependent. The highest-risk mistake is treating “exosomes” as a generic commodity rather than a defined biologic product.
02Executive Summary
Extracellular vesicles (EVs) are lipid-bilayer nanoparticles released by cells. The subtype historically called exosomes overlaps with what the International Society for Extracellular Vesicles now often recommends describing more operationally as small extracellular vesicles because isolation methods rarely prove endosomal origin with certainty. MISEV2023 (PMID: 38326288) is the current consensus standard for EV nomenclature, characterization, and reporting.
For Heretic purposes, exosome therapy sits at the intersection of PRP and Stem Cell Therapies, Peptide Therapy for Injuries, Overview - Regenerative Medicine, Frequency-Specific Microcurrent, Overview - Photobiomodulation, and NAD+ IV Therapy. It is attractive because most clinical benefit from “stem-cell” interventions likely comes from paracrine signaling rather than durable engraftment. Exosomes are one candidate carrier for those signals.
Bottom line:
- Most defensible near-term uses: research-grade wound healing, inflammatory lung injury, orthopedic/cartilage repair, and local tissue regeneration trials.
- Most overmarketed uses: generalized “anti-aging,” autism, dementia reversal, fertility rejuvenation, and broad immune “reset” protocols sold outside trials.
- Regulatory reality: FDA states there are currently no FDA-approved exosome products for treating diseases or conditions in humans and has warned about serious adverse events from unapproved products.
- Key due-diligence question: What exactly is in the vial — source cell, culture conditions, isolation method, particle count, potency assay, sterility/endotoxin/mycoplasma testing, and release criteria?
03What Are Exosomes?
Definitions
Extracellular vesicles (EVs) are membrane-bound particles released by cells and unable to replicate. They carry proteins, lipids, nucleic acids, metabolites, and surface ligands that can alter recipient-cell behavior.
Exosomes are classically defined as ~30–150 nm EVs formed inside multivesicular bodies and released when those bodies fuse with the plasma membrane. In practice, most clinical products called “exosomes” are better described as small extracellular vesicle preparations, because size alone does not prove biogenesis.
Why nomenclature matters:
- A product can contain exosomes, microvesicles, protein aggregates, lipoproteins, cytokines, albumin, culture-media residues, or contaminants.
- Particle count alone can be misleading if most particles are non-vesicular debris.
- Therapeutic potency depends on cargo and functional activity, not just nanoparticle number.
Typical Cargo
| Cargo class | Examples | Why it matters |
|---|---|---|
| Surface proteins | CD9, CD63, CD81, integrins, adhesion molecules | Uptake, targeting, identity markers |
| Growth-factor signals | VEGF-related angiogenic signaling, TGF-β family signals, IGF-axis effects | Repair, angiogenesis, fibrosis risk depending context |
| miRNA / RNA cargo | miR-21, miR-126, miR-146a, miR-140 and many tissue-specific miRNAs | Gene-expression modulation in recipient cells |
| Lipids | Sphingomyelin, cholesterol, phosphatidylserine | Membrane stability, immune recognition, uptake |
| Metabolites / enzymes | Redox and metabolic mediators | Mitochondrial and inflammatory effects |
Swipe table →
Exosomes vs Stem Cells
| Aspect | Living stem/stromal cell therapy | Exosome / sEV therapy |
|---|---|---|
| Main mechanism | Paracrine signaling plus possible limited cell persistence | Paracrine signaling only |
| Replication | Cells can survive, divide, differentiate, senesce, or die | Acellular; cannot replicate |
| Tumor/ectopic tissue risk | Theoretical and product-dependent | Lower, but not automatically zero-risk if pro-growth signals are misused |
| Immune complexity | Living allogeneic cells may interact dynamically with host immunity | Still immunologically active; cargo and donor/source matter |
| Manufacturing | Cell expansion + viability/potency controls | Cell culture + EV isolation + purity/potency controls |
| Dosing units | Cell number, viability, phenotype | Particles, protein, EV markers, and ideally potency assay |
| Regulatory path | Biologic / cell therapy | Biologic / drug; not exempt just because acellular |
Swipe table →
04Mechanisms of Action
1. Paracrine Repair Signaling
Many regenerative effects attributed to MSCs appear to be mediated by secreted factors rather than engraftment. Exosomes are one packaging system for that paracrine secretome.
Donor cell state + culture conditions
↓
EV cargo: proteins, lipids, miRNAs, metabolites
↓
Recipient cell uptake or receptor binding
↓
Altered gene expression and immune tone
↓
Repair, angiogenesis, anti-inflammatory shift, matrix remodeling
2. Immunomodulation
MSC-derived EVs can shift macrophage phenotype, reduce pro-inflammatory cytokine signaling, influence T-cell balance, and promote resolution biology in some models. This is the reason they are studied in inflammatory lung injury, autoimmune models, osteoarthritis, and wound healing.
Important caveat: “immunomodulatory” does not always mean beneficial. In cancer, chronic infection, or poorly characterized immune dysfunction, pro-resolution signaling could theoretically suppress needed immune surveillance.
3. Matrix and Cartilage Signaling
In osteoarthritis models, MSC-exosomes often increase anabolic cartilage markers such as collagen II and aggrecan while reducing catabolic mediators such as MMP-13, TNF-α, IL-1β, and IL-6. A 2025 systematic review/meta-analysis of rat knee OA studies (PMID: 40529485) found consistent histological improvements across OARSI, Mankin, and ICRS scoring systems, but the evidence was still preclinical.
4. Angiogenesis and Wound Repair
EVs from mesenchymal stromal cells can carry pro-angiogenic and matrix-remodeling signals. This is relevant to chronic wounds, burns, ischemic tissue, and tendon/ligament healing. The practical challenge is dose, route, source-cell state, and whether angiogenesis is desirable in a given context.
5. Drug-Delivery Platform Potential
Engineered exosomes may eventually deliver siRNA, mRNA, proteins, or small molecules. This is conceptually powerful because EVs are biologically tolerated carriers with natural cell-entry mechanisms. However, engineered EV drug delivery is closer to a pharmaceutical platform than a clinic-office “anti-aging” injection.
05Source Cell Types
| Source | Claimed advantages | Main concerns |
|---|---|---|
| Umbilical cord MSCs | Young donor biology, strong expansion capacity, common in commercial products | Donor screening, batch consistency, perinatal tissue regulation |
| Placental MSCs | Immunomodulatory signaling; early severe COVID-19 RCT signal | Product-specific; pregnancy tissue sourcing and screening |
| Bone marrow MSCs | Historical stem-cell literature base; orthopedic relevance | Older donors may produce less regenerative cargo |
| Adipose-derived MSCs | Abundant, autologous workflows possible | SVF/adipose regulatory issues; inflammatory donor state matters |
| Synovial fluid MSCs | Cartilage/joint tropism suggested in OA models | Less common commercially; mostly preclinical |
| Platelet-derived EVs | Link to PRP and Stem Cell Therapies, hemostasis and wound repair | Platelet activation state changes cargo; thrombosis/inflammation questions |
| Immune-cell EVs | Targeted immunotherapy potential | Higher immunological complexity |
Swipe table →
Donor and Culture Conditions Matter
The donor cell is not a static “factory.” EV cargo changes with:
- donor age, sex, disease burden, and medications
- passage number and cellular senescence
- oxygen tension / hypoxic preconditioning
- inflammatory priming (e.g., IFN-γ, TNF-α exposure)
- serum-free vs serum-containing culture
- 2D culture vs bioreactor expansion
- harvest timing and storage conditions
A high-quality exosome product should therefore disclose not only the source cell, but also the production logic and release specifications.
06Evidence Map
Evidence Ratings Used Here
| Rating | Meaning |
|---|---|
| 5 | Multiple replicated human RCTs / meta-analyses for the specific indication |
| 4 | At least one credible human RCT or strong clinical controlled evidence |
| 3 | Early human data plus strong mechanism/preclinical support |
| 2 | Mostly animal/in vitro evidence with plausible mechanism |
| 1 | Anecdote, marketing, or speculative extrapolation |
Swipe table →
By Indication
| Indication | Evidence strength | What is known | Key caveat |
|---|---|---|---|
| Severe COVID-19 / ARDS | 3–4 | Small double-blind RCT of placental MSC-sEVs reported lower mortality (PMID: 39051747) | Small N=45; pandemic-specific disease; needs replication |
| Knee osteoarthritis / cartilage repair | 2–3 | Strong animal meta-analysis signal; synovial/umbilical sources promising (PMID: 40529485) | Mostly preclinical; human protocols not standardized |
| Chronic wounds / burns | 2–3 | Mechanistically plausible; strong animal and early translational interest | Few mature human trials; topical/local product quality critical |
| Orthopedic tendons/ligaments | 2 | Plausible matrix and inflammation effects | Human outcomes often extrapolated from PRP/stem-cell clinic data |
| Skin rejuvenation / hair restoration | 1–2 | Local trophic effects plausible | Commercial market far ahead of evidence |
| Neurodegeneration / TBI | 1–2 | Intranasal EV delivery and neuroinflammation data intriguing | Human efficacy not established; CNS targeting unclear |
| General longevity / “anti-aging IV” | 1 | Systemic rejuvenation conceptually attractive | No validated clinical endpoint, dose, frequency, or long-term safety dataset |
Swipe table →
07Human Clinical Evidence
Severe COVID-19 RCT: Placental MSC-sEVs
A 2024 double-blind randomized controlled trial tested human placental mesenchymal stromal cell-derived small EVs in patients with COVID-19-associated ARDS (PMID: 39051747).
| Feature | Details |
|---|---|
| Design | Double-blind randomized controlled clinical trial |
| Participants | 45 severe COVID-19 / ARDS patients |
| Intervention | Standard treatment + hPMSC-sEVs |
| Control | Standard treatment + placebo |
| Primary outcome | Hospital deaths |
| Reported mortality | 4/21 intervention (19.04%) vs 13/24 control (54.16%), p=0.015 |
| Interpretation | Strong signal for a small early RCT; not proof of broad exosome efficacy |
Swipe table →
This is one of the more interesting human signals because it uses a controlled design rather than an open-label wellness-clinic series. Still, it does not justify generalized anti-aging use; it supports further trials in severe inflammatory lung injury and related indications.
Severe COVID-19 Open-Label Study: Bone Marrow MSC Exosomes
Sengupta et al. reported an open-label prospective cohort using bone-marrow MSC-derived exosomes in severe COVID-19 (PMID: 32380908). The study reported safety and improvement signals, but the absence of randomization and pandemic-era confounding limit inference.
Orthopedic / OA Evidence
The OA literature is mechanistically coherent but still mostly preclinical. The 2025 rat-model meta-analysis (PMID: 40529485) found:
- 28 preclinical studies included
- improved cartilage histology scores
- increased collagen II, aggrecan, and IL-10
- reduced IL-1β, IL-6, MMP-13, and TNF-α
- synovial-fluid MSC and umbilical MSC exosomes looked especially promising
- twice-weekly dosing appeared more effective than weekly dosing in animal models
Translation warning: Rat-joint injection frequency does not equal a human clinical protocol. Joint volume, disease stage, immune state, mechanical load, and product potency all change translation.
08Regulatory Status and Safety
United States
The FDA consumer alert states that exosome products intended to treat diseases or conditions generally require FDA approval and that there are currently no FDA-approved exosome products. The FDA also issued a 2019 public safety alert after serious adverse events in Nebraska linked to products marketed as containing exosomes.
Practical implication: In the U.S., commercial “exosome therapy” offered outside an IND-authorized clinical trial is a regulatory red flag, even if the mechanism is plausible.
Why the FDA Concern Is Not Just “Pharma Gatekeeping”
A skeptical Heretic stance should distinguish two different claims:
- The biology is real. EVs are legitimate intercellular signaling systems with therapeutic potential.
- The marketplace is messy. A poorly characterized vial marketed as “50 billion exosomes” may be biologically undefined, contaminated, degraded, mislabeled, or clinically untested.
The regulatory problem is partly institutional conservatism, but also partly a real manufacturing and safety problem.
Safety Concerns
| Risk | Why it matters |
|---|---|
| Contamination | Sterility, endotoxin, mycoplasma, residual media, adventitious agents |
| Pro-growth signaling | Potential concern in active malignancy or premalignant lesions |
| Immune effects | May worsen some immune states or blunt needed inflammatory defense |
| Thrombo-inflammatory effects | IV nanoparticles and tissue-factor contamination are theoretical/observed concerns in cell products |
| Product heterogeneity | “Same dose” may not mean same bioactivity across batches |
| Delayed standard care | Patients may pursue expensive unapproved treatments for serious disease |
Swipe table →
09Quality and Sourcing Framework
Minimum Due-Diligence Checklist
Ask for documentation before considering any exosome/sEV product:
- Source cell identity — MSC? placental? umbilical? donor-screening criteria?
- Culture method — passage number, media, serum-free conditions, oxygen tension, priming.
- Isolation method — ultracentrifugation, size-exclusion chromatography, tangential-flow filtration, precipitation kits, immunoaffinity, or mixed workflow.
- Characterization — nanoparticle tracking analysis, electron microscopy or equivalent morphology, protein markers (CD9/CD63/CD81), negative markers, protein:particle ratio.
- Potency assay — not just particle count; e.g., macrophage cytokine assay, angiogenesis assay, chondrocyte matrix assay, wound-closure assay.
- Release testing — sterility, endotoxin, mycoplasma, residual DNA, residual host-cell proteins, viral screening where relevant.
- Storage stability — freeze/thaw history, validated shelf life, shipping temperature logs.
- Clinical protocol — indication, route, dose, schedule, monitoring, adverse-event plan.
- Regulatory status — IND number or trial registration if used for disease treatment in the U.S.
- Conflict of interest — clinic selling product should not be sole source of evidence.
MISEV2023-Informed Reporting Standard
MISEV2023 (PMID: 38326288) emphasizes rigorous reporting around EV nomenclature, separation, characterization, and functional studies. For this knowledge base, claims about exosome products should be downgraded if they lack:
- clear EV vs non-EV particle distinction
- at least three positive EV markers or source-appropriate markers
- negative controls for contaminants
- functional potency assay
- transparent production and storage method
- adverse-event reporting
10Practical Notes
Clinical-Use Heuristics
This section is a research and due-diligence framework.
More defensible contexts:
- IRB-approved / IND-authorized clinical trial
- severe disease with plausible mechanism and monitoring
- local orthopedic or wound application with clear endpoints
- practitioner can explain source, dose, assay, and risk plan
Less defensible contexts:
- “annual anti-aging exosome IV” with no biomarker endpoint
- products advertised as stem cells but actually conditioned media
- no certificate of analysis
- no adverse-event plan
- claims to treat many unrelated diseases with one product
- pricing based on “billions of particles” without potency data
Route Considerations
| Route | Logic | Main unknowns |
|---|---|---|
| Local injection | Higher concentration at tissue target; orthopedic/wound logic | Dose, tissue retention, post-injection inflammation |
| Topical / microneedling | Skin and wound applications | Penetration, sterility, cosmetics vs biologic boundary |
| IV infusion | Systemic immune or inflammatory indications | Biodistribution, lung/liver/spleen uptake, coagulation and immune effects |
| Intranasal | CNS targeting hypothesis | Human delivery efficiency, dosing, safety |
| Intra-articular | Cartilage/synovium targeting | Product persistence, disease stage, mechanical load |
Swipe table →
Uses
Commercial protocols often describe doses such as 1–20 × 10¹⁰ particles per treatment. This is not a validated universal dose. Particle count is a weak surrogate unless normalized to:
- EV purity
- source cell type
- cargo profile
- potency assay
- route
- target tissue
- disease severity
A smaller number of high-potency, well-characterized EVs may be more meaningful than a large number of undefined particles.
Combination Strategies
Possible rational combinations include:
- PRP and Stem Cell Therapies — platelet-derived growth-factor environment plus EV signaling
- Overview - Photobiomodulation — mitochondrial and local tissue signaling support
- Hyperbaric Oxygen Therapy — wound oxygenation and angiogenesis context
- Peptide Therapy for Injuries — BPC-157/TB-500 style repair signaling, with evidence caveats
- Mitochondrial Health — systemic repair requires ATP and redox capacity
Avoid stacking advanced interventions without clear endpoints; otherwise the signal becomes uninterpretable.
11Red Flags in Commercial Claims
Marketing Red Flags
- “FDA registered” used to imply FDA approval
- “No side effects because natural”
- “Treats autism, Alzheimer’s, long COVID, arthritis, infertility, and anti-aging” in one package
- no specific source cell or isolation method
- no certificate of analysis
- no particle-size distribution or marker panel
- no potency assay
- before/after testimonials as primary evidence
- aggressive claims about “stem cells without stem-cell regulation”
Scientific Red Flags
- uses “exosome,” “secretome,” “conditioned media,” and “growth factors” interchangeably
- reports protein concentration but not particle count or EV markers
- reports particle count but not purity or potency
- no negative markers for non-EV contamination
- no batch-to-batch variability data
- no route-specific biodistribution logic
12Research Directions
High-Value Questions
- Potency assays: Which in-vitro assays best predict clinical outcomes for wounds, cartilage, lung injury, and immune conditions?
- Source optimization: Which donor-cell sources and culture conditions produce the most therapeutic cargo for each indication?
- Dose-response: Is there a hormetic window where too little does nothing and too much causes inflammatory/pro-growth noise?
- Biodistribution: Where do injected EVs go by route, and how long do they persist?
- Cancer biology: Can pro-regenerative signaling worsen tumor microenvironments in susceptible patients?
- Aging claims: Which biomarkers would prove systemic rejuvenation rather than transient inflammatory modulation?
- Comparative effectiveness: Exosomes vs PRP vs MSCs vs peptides vs photobiomodulation for the same endpoint.
Best Future Trial Designs
- indication-specific, not generic wellness
- product fully characterized to MISEV2023 standards
- pre-registered primary endpoint
- placebo/sham control where feasible
- biomarker panel before and after
- adverse-event follow-up beyond the immediate injection window
- batch-lot tracking for every participant
13Evidence Strength Summary
| Claim | Current rating | Comment |
|---|---|---|
| EVs are real biological signaling particles | 5 | Basic biology consensus |
| MSC-EVs can modulate inflammation and repair in models | 4 | Strong preclinical reproducibility |
| Exosomes are safer than living-cell therapy | 3 | Plausible but product- and route-dependent |
| Exosomes improve severe inflammatory lung disease | 3 | Small RCT signal; needs replication |
| Exosomes regenerate cartilage in humans | 2 | Animal signal strong; human proof limited |
| Exosome IVs reverse aging | 1 | Currently speculative / commercial extrapolation |
| Any clinic product labeled “exosomes” is equivalent | 0 | False; manufacturing determines identity and potency |
Swipe table →
14Notes
- Terminology contradiction: Clinics prefer the word “exosomes” because it sounds precise; ISEV-style scientific language often prefers “EVs” or “small EVs” unless biogenesis is demonstrated.
- Regulatory contradiction: The FDA’s caution is justified for undefined products, but excessive regulatory friction may also slow legitimate acellular regenerative therapies.
- Evidence gap: Some of the strongest human signals are in acute severe inflammatory disease, not anti-aging clinics.
- Measurement problem: Particle count is the “milligram dose” fallacy of exosome therapy — easy to sell, insufficient to prove activity.
- Potential lost-knowledge angle: Soviet/Russian bioregulator work focused on peptide signaling as tissue-specific information. Exosome therapy may be a modern vesicular analog of the same first-principles idea: repair is informational, not merely structural. See Peptide Bioregulation (Khavinson) and Khavinson Peptides (Russian Bioregulators).
15Exosome Therapy: Evidence and Clinical Translation
Overview
Exosome therapy (extracellular vesicle preparations, primarily MSC-derived) is expanding in regenerative and longevity clinics. Regulatory status remains gray: zero FDA-approved exosome products for any therapeutic use as of mid-2026. All therapeutic exosomes require BLA/IND pathway (Section 351 biologics). FDA has issued multiple warnings and consumer alerts. However, the broader MSC therapy field saw its first FDA approval in December 2024 (Ryoncil/remestemcel-L), and several EV-based products are now in advanced clinical trials — making this a field in rapid regulatory transition.
Regulatory Milestone — Ryoncil (Remestemcel-L) Approval
The December 2024 FDA approval of Ryoncil (Mesoblast) — the first-ever MSC therapy — for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients ≥2 months is a landmark for the entire MSC-EV field:
- Why it matters for exosomes: MSC-EVs are derived from the same cell populations. Ryoncil's approval validates MSC expansion and manufacturing processes that EV products depend on. It establishes a regulatory precedent for immunomodulatory biologics from MSC sources.
- What it does NOT do: Ryoncil is a cell therapy, not an EV product. It does not constitute FDA approval of exosomes. The remaining manufacturing challenge for EVs is downstream processing — isolation, characterization, and potency testing of vesicles themselves.
- Potency lesson: Ryoncil's path (including prior CRLs) underscores that robust potency assays are the critical regulatory hurdle. EV products will face the same bar.
- Source: PMID: 39028333 (editorial, Extracellular Vesicles and Circulating Nucleic Acids)
Regulatory Status (2026)
- FDA Position: Zero approved exosome/EV products. All therapeutic use requires full BLA/IND pathway (Section 351 biologics — safety, efficacy, potency).
- No Section 361 pathway: Exosomes do not qualify for the "minimally manipulated" exception in most applications.
- Active enforcement: Warning letters and public safety notifications continue. Clinics marketing direct-to-consumer ($3k–$15k/injection) face enforcement risk.
- "FDA-registered" ≠ "FDA-approved": A facility can be FDA-registered as a tissue establishment without any product review. This distinction is frequently exploited in clinic marketing.
- International: Japan, Mexico, and Panama host clinics offering exosome therapies outside FDA jurisdiction. Quality and oversight vary widely.
Evidence Gaps & Critical Unknowns
- No large Phase 3 efficacy data for any pure EV product (ExoFlo EXTINGUISH ARDS is the first to reach this scale).
- Standardization absent: No consensus on dosing units (particles vs. protein vs. vesicle count), sourcing (MSC, cord, placental), or potency assays.
- Long-term safety unknowns: Immunogenicity, tumorigenicity, and biodistribution of IV-administered EVs are under-characterized.
- Product identity crisis: Many "exosome" products are actually conditioned media, secretome, or protein aggregates. Without MISEV2023-compliant characterization (CD9/CD63/CD81 markers, NTA, TEM), product claims are unverifiable.
Commercial & Clinic Landscape
- Legitimate pipeline players: Direct Biologics, Capricor, Aegle, Kimera Labs, EVast Bio.
- Market size: ~$58.1B in 2026, projected $309.6B by 2035 (industry estimates — treat with caution).
- Gray market clinics: Numerous clinics offering "exosome therapy" for longevity, joint pain, and skin — typically without IND authorization or product characterization.
- Claims audit priority: Longevity clinics must limit to investigational framing; avoid disease-treatment claims. Disease-treatment claims (e.g., "treats Alzheimer's," "cures arthritis") trigger FDA enforcement.
16Connections
17Sources
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13(2):e12404. PMID: 38326288 .PubMed 38326288
- Wang et al. Mesenchymal stem cell-derived exosomes for the treatment of knee osteoarthritis: a systematic review and meta-analysis based on rat model. 2025. PMID: 40529485 .PubMed 40529485
- Human placental mesenchymal stromal cell-derived small extracellular vesicles as a treatment for severe COVID-19: a double-blind randomized controlled clinical trial. Journal of Extracellular Vesicles. 2024. PMID: 39051747 .PubMed 39051747
- Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells and Development. 2020. PMID: 32380908 .PubMed 32380908
- PubMed 39028333PubMed 39028333
18Entry history
Latest content update.
Folded in 1 earlier page: exosome-therapy-clinical-translation.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.